Passage Bio Inc PASG.OQ PASG.O is expected to show no change in quarterly revenue when it reports results on August 6 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for Passage Bio Inc is for a loss of $4.05 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Passage Bio Inc is $100.00, about 94.3% above its last closing price of $5.74
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -4.61 | -4.60 | -5.00 | Missed | -8.7 |
Dec. 31 2025 | -4.53 | -4.08 | -4.00 | Beat | 2 |
Sep. 30 2024 | -4.23 | -4.60 | -6.20 | Missed | -34.8 |
Jun. 30 2024 | -6.11 | -6.20 | -5.20 | Beat | 16.1 |
Mar. 31 2024 | -7.22 | -7.15 | -6.00 | Beat | 16.1 |
Dec. 31 2023 | -7.99 | -8.04 | -6.00 | Beat | 25.3 |
Sep. 30 2023 | -9.48 | -9.12 | -9.80 | Missed | -7.4 |
Jun. 30 2023 | -9.43 | -9.57 | -8.80 | Beat | 8 |
This summary was machine generated August 4 at 13:25 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。